In fact, it’s easy to think of many different reforms that would bring private capital gushing in to the pharma sector. So why is it that the pharma companies haven’t thought to ask for such powerful  incentives?   Why didn’t they hold out the promise of, say, a Salk Vaccine for Alzheimer’s?   We can only answer with a sigh, and with a reminder of Talleyrand’s apothegm: 